Optimizing mRNA For Success: A Guide To Enhanced Stability, Delivery, And Efficacy
By Conner Feldman, MilliporeSigma
The COVID-19 pandemic has spurred a surge in investment and research directed at mRNA therapeutics. These drugs hold promise for the rapid development of vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing remain.
A key advantage of mRNA is its speedy development, making it ideal for tackling emerging infectious diseases. Additionally, mRNA therapeutics offer design flexibility, allowing for easy modification to target various illnesses. This technology shows promise for personalized cancer vaccines and other targeted treatments. Despite its advantages, mRNA faces hurdles: importantly, unprotected mRNA is fragile and requires specific handling and storage conditions, and current delivery systems using lipid nanoparticles can target unintended tissues and have issues related to long-term stability.
Researchers are actively exploring solutions — advancements in design, codon optimization, and manufacturing can improve mRNA safety, efficacy, and stability. Alternative delivery vehicles like self-replicating mRNA and tissue-targeted nanoparticles are being investigated. Additionally, high-resolution analytical techniques like next-generation sequencing are crucial for characterizing mRNA sequences and impurities.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.